26 related articles for article (PubMed ID: 15602112)
21. Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT
Poyurovsky M; Weizman A
Drugs; 2020 Jun; 80(9):871-882. PubMed ID: 32385739
[TBL] [Abstract][Full Text] [Related]
22. The 5-HT1D receptor agonist zolmitriptan for neuroleptic-induced akathisia: an open label preliminary study.
Gross-Isseroff R; Magen A; Shiloh R; Hermesh H; Weizman A
Int Clin Psychopharmacol; 2005 Jan; 20(1):23-5. PubMed ID: 15602112
[TBL] [Abstract][Full Text] [Related]
23. Review of zolmitriptan and its clinical applications in migraine.
Dowson AJ; Charlesworth B
Expert Opin Pharmacother; 2002 Jul; 3(7):993-1005. PubMed ID: 12083998
[TBL] [Abstract][Full Text] [Related]
24. Zolmitriptan: a review of its use in migraine.
Spencer CM; Gunasekara NS; Hills C
Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
[TBL] [Abstract][Full Text] [Related]
25. Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older.
McKeage K
Paediatr Drugs; 2016 Feb; 18(1):75-81. PubMed ID: 26747634
[TBL] [Abstract][Full Text] [Related]
26. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis.
Laoutidis ZG; Luckhaus C
Int J Neuropsychopharmacol; 2014 May; 17(5):823-32. PubMed ID: 24286228
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
